NEW YORK, April 12, 2023 /PRNewswire/ -- The Ewing's sarcoma treatment market size is forecast to increase by USD 302.5 million from 2021 to 2026, at a CAGR of 5.9%, according to the recent market study by Technavio. The growth of the market will be driven by the growing awareness about and funding for Ewing's sarcoma, regulatory incentives, and financial assistance programs and reimbursements schemes. Technavio offers an up-to-date analysis of the current global market scenario and the overall market environment. View Sample Report
Technavio categorizes the global ewing's sarcoma treatment market Vendor Analysis:
The global Ewing's sarcoma treatment market is currently a moderately fragmented market with chemotherapy drugs and a limited number of approved targeted therapies. Technavio has extensively analyzed 15 major vendors, including Advenchen Laboratories LLC, Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Gradalis Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., PharmaMar SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Vendor Offerings -
- Amneal Pharmaceuticals Inc. - The company offers Ewing's sarcoma treatment solution namely Cyclophosphamide.
- Baxter International Inc. - The company offers Ewing's sarcoma treatment solution namely IFEX.
- Bristol Myers Squibb Co. - The company offers Ewing's sarcoma treatment solution namely Etopophos.
Charts & data tables about market and segment sizes during forecast period (2022-2026) have been covered in this report. Download The Sample Report
Key Benefits for Industry Players & Stakeholders –
- The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
- It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
- The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Expand operations in the future - To get requisite details, ask for a custom report.
Get a holistic overview of the endoscopic closure devices market by industry experts to evaluate and develop growth strategies. Download the Sample
Market Segmentation:
The report extensively covers Ewing's sarcoma treatment market segmentations by type (combination therapy and monotherapy) and geography (North America, Europe, Asia, and Rest of World (ROW)).
- The market share growth by the combination therapy segment will be significant during the forecast period. Presently, as per therapy rules, chemotherapy is utilized as the first-line therapy, trailed by a medical procedure or radiation treatment, to treat Ewing's sarcoma. The significance of mix chemotherapy in the therapy of restricted Ewing's sarcoma is high. Patients with these growths, who don't display disease spread in bone marrow biopsy tests, are supposed to have areas of malignant growth spread that are excessively little for distinguishing proof in symptomatic tests. Therefore, these small metastases would eventually grow into larger tumors if these patients did not receive chemotherapy. Combination chemotherapy, followed by radiation therapy or surgery, is chosen for metastatic tumors. During the forecast period, the market growth will be boosted by this growing demand for combination therapy.
Market Dynamics:
Key DRIVERS:
- The growing awareness about and funding for Ewing's sarcoma is one of the major drivers supporting the Ewing's sarcoma treatment market growth.
- Patients with Ewing's sarcoma are supported and educated by numerous independent sarcoma organizations, including CureResearch and the Sarcoma Foundation of America.
- These campaigns emphasized raising funds for sarcoma research and awareness. It is still regarded as a neglected form of cancer. Because of this lack of awareness, efforts to encourage research and drug development are more difficult.
- As a result, the month of July is designated as Sarcoma Awareness Month, when a variety of organizations organize educational events to spread awareness among Ewing's sarcoma patients worldwide.
- Similarly, the Allandale family's campaign and the Liddy Shriver Sarcoma Initiative are dedicated to raising funds for high-quality research and raising awareness of sarcoma, both of which aim to enhance the quality of life for people with the disease.
- Hence, during the forecast period, such factors are anticipated to propel the growth of the Ewing's sarcoma treatment market.
Major Trends:
- The strong pipeline is one of the major Ewing's sarcoma treatment market trends that is contributing to the market growth.
- For instance, Peking University People's Hospital is currently carrying out one of the studies to evaluate a combination of vincristine, irinotecan, and temozolomide in patients with relapsed and metastatic Ewing's sarcoma.
- Phase II clinical trials are currently underway for the study. In a similar vein, an investigation into the safety and efficacy of nivolumab and ipilimumab for the treatment of Ewing's sarcoma is being carried out by Assaf-Harofeh Medical Center in Israel.
- The high safety and efficacy profile of the drugs in development is anticipated to accelerate their approval during the forecast period. Consequently, during the forecast period, the robust pipeline for Ewing's sarcoma and anticipated new approvals will contribute to the market's expansion.
Key Challenges:
- The lack of approved therapies for Ewing's sarcoma is one of the challenges hindering the Ewing's sarcoma treatment market growth.
- There are currently no FDA-approved targeted therapies on the market. Ewing's sarcoma patients can only be treated with chemotherapeutics at this time.
- Despite new treatments' improved efficacy and higher survival rates, chemotherapeutic side effects continue to be a major source of concern for patients.
- Chemotherapy patients most frequently experience nausea and vomiting as side effects. Deferred intense chemotherapy-actuated sickness and regurgitating are challenging to oversee in patients.
- The second most common side effect of chemotherapy is gastrointestinal side effects, which can be painful and fatal. These potentially fatal side effects may impede the expansion of the Ewing's sarcoma treatment market, during the forecast period.
To get detailed insights about inclusions and exclusions, buy the report
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
What are the key data covered in this Ewing's sarcoma treatment market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the Ewing's sarcoma treatment market between 2022 and 2026
- Precise estimation of the size of the Ewing's sarcoma treatment market and its contribution to the market with a focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the Ewing's Sarcoma Treatment Market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of Ewing's Sarcoma Treatment Market vendors
Related Reports:
The kaposi sarcoma market size has the potential to grow by USD 20.89 million during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 3.10%. This report provides a detailed analysis of the market by treatment type (HAART, chemotherapy, and immunotherapy), geography (North America, Europe, Asia, and ROW), and key vendors. The rising number of organ transplants will drive the global kaposi sarcoma market growth during the estimated period.
The sarcoma therapeutics market size is expected to increase by USD 1.18 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9%. The report extensively covers sarcoma therapeutics market segmentation by type (soft tissue sarcoma and osteosarcoma) and geography (North America, Europe, APAC, and Rest of the World (ROW)). One of the factors driving the global sarcoma therapeutics market growth is the patient assistance programs due to the increasing cost of therapeutics for the treatment of various oncology indications.
Ewing's Sarcoma Treatment Market Scope |
|
Report Coverage |
Details |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.9% |
Market growth 2022-2026 |
USD 302.5 million |
Market structure |
Fragmented |
YoY growth 2022-2023 (%) |
5.51 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 50% |
Key countries |
US, Canada, UK, Germany, Japan, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Advenchen Laboratories LLC, Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Gradalis Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., PharmaMar SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse for Technavio's Health Care Market Reports
Table of contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Combination therapy - Market size and forecast 2021-2026
- Exhibit 28: Chart on Combination therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Combination therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Combination therapy - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Combination therapy - Year-over-year growth 2021-2026 (%)
- 5.4 Monotherapy - Market size and forecast 2021-2026
- Exhibit 32: Chart on Monotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Monotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Monotherapy - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Monotherapy - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Canada - Market size and forecast 2021-2026
- Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 Germany - Market size and forecast 2021-2026
- Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.11 Japan - Market size and forecast 2021-2026
- Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)
- 7.12 China - Market size and forecast 2021-2026
- Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.13 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 86: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 87: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification
- 10.3 Amneal Pharmaceuticals Inc.
- Exhibit 89: Amneal Pharmaceuticals Inc. - Overview
- Exhibit 90: Amneal Pharmaceuticals Inc. - Business segments
- Exhibit 91: Amneal Pharmaceuticals Inc. - Key news
- Exhibit 92: Amneal Pharmaceuticals Inc. - Key offerings
- Exhibit 93: Amneal Pharmaceuticals Inc. - Segment focus
- 10.4 Baxter International Inc.
- Exhibit 94: Baxter International Inc. - Overview
- Exhibit 95: Baxter International Inc. - Business segments
- Exhibit 96: Baxter International Inc. - Key offerings
- Exhibit 97: Baxter International Inc. - Segment focus
- 10.5 Bristol Myers Squibb Co.
- Exhibit 98: Bristol Myers Squibb Co. - Overview
- Exhibit 99: Bristol Myers Squibb Co. - Product / Service
- Exhibit 100: Bristol Myers Squibb Co. - Key offerings
- 10.6 Eli Lilly and Co.
- Exhibit 101: Eli Lilly and Co. - Overview
- Exhibit 102: Eli Lilly and Co. - Product / Service
- Exhibit 103: Eli Lilly and Co. - Key offerings
- 10.7 Merck and Co. Inc.
- Exhibit 104: Merck and Co. Inc. - Overview
- Exhibit 105: Merck and Co. Inc. - Business segments
- Exhibit 106: Merck and Co. Inc. - Key news
- Exhibit 107: Merck and Co. Inc. - Key offerings
- Exhibit 108: Merck and Co. Inc. - Segment focus
- 10.8 Novartis AG
- Exhibit 109: Novartis AG - Overview
- Exhibit 110: Novartis AG - Business segments
- Exhibit 111: Novartis AG - Key offerings
- Exhibit 112: Novartis AG - Segment focus
- 10.9 Pfizer Inc.
- Exhibit 113: Pfizer Inc. - Overview
- Exhibit 114: Pfizer Inc. - Product / Service
- Exhibit 115: Pfizer Inc. - Key news
- Exhibit 116: Pfizer Inc. - Key offerings
- 10.10 PharmaMar SA
- Exhibit 117: PharmaMar SA - Overview
- Exhibit 118: PharmaMar SA - Business segments
- Exhibit 119: PharmaMar SA - Key news
- Exhibit 120: PharmaMar SA - Key offerings
- Exhibit 121: PharmaMar SA - Segment focus
- 10.11 Teva Pharmaceutical Industries Ltd.
- Exhibit 122: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 123: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 124: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 125: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 126: Teva Pharmaceutical Industries Ltd. - Segment focus
- 10.12 Viatris Inc.
- Exhibit 127: Viatris Inc. - Overview
- Exhibit 128: Viatris Inc. - Business segments
- Exhibit 129: Viatris Inc. - Key offerings
- Exhibit 130: Viatris Inc. - Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 131: Inclusions checklist
- Exhibit 132: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 133: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 134: Research methodology
- Exhibit 135: Validation techniques employed for market sizing
- Exhibit 136: Information sources
- 11.5 List of abbreviations
- Exhibit 137: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article